The Latest Breaking News from Eli Lilly

Earlier this month, the FDA approved Eli Lilly's Zepbound, a drug similar to its diabetes drug Mounjaro but specifically advertised for weight loss.

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this year from Eli Lilly.

Zepbound is expected to be available in the U.S. by the end of the year.

Novo Nordisk stock skidded Tuesday after Eli Lilly's weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study.

Google leads this watchlist of five S&P 500 stocks near buy points as the market rally has investors seeing green.

Eli Lilly stock is Monday's IBD Stock Of The Day. Shares are forming a new flat base after the FDA approved Lilly's new weight-loss drug.

Several pharmaceutical companies are racing to develop obesity drugs and tap into a surge in consumer demand for the extremely profitable drugs. Sales of Eli Lilly’s (LLY ) diabetes drug Mounjaro, just approved by the U.S. Food and Drug Administration (FDA) for obesity in the U.S., hit $1.41 billion in...

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

This iron condor trade on Eli Lilly stock has the potential to return 27% if the stock price stays between about 510 and 680.